EHA 2018 | Improved survival in MM with thalidomide before and after ASCT

Niels van de Donk

The 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, presented exciting data for multiple myeloma (MM). In this interview, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses the long-term results of the HOVON-50 study (NCT00028886), which investigated thalidomide/adriamycine/dexamethasone (TAD) followed by high-dose melphalan/ASCT and thalidomide maintenance therapy. This exciting study showed improved survival with thalidomide use prior to and following transplant.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter